Access
This article is part of Nature's premium content.
Published online 30 January 2008 |
Nature
451,
509
(2008)
| doi:10.1038/451509a
Updated online: 30 January 2008
News
Reviewer leaked Avandia study to drug firm
GlaxoSmithKline told early of diabetes blockbuster's links to heart attacks.
A peer reviewer for The New England Journal of Medicine (NEJM) broke confidentiality and leaked a damaging report about the blockbuster diabetes drug Avandia to the drug's manufacturer weeks ahead of publication, Nature has learned.
Avandia (rosiglitazone) came under heavy scrutiny after 21 May 2007, when the NEJM published online a meta-analysis1 of other studies into the drug's efficacy and safety.
To read this story in full you will need to login or make a payment (see right).
Comments
Reader comments are usually moderated after posting. If you find something offensive or inappropriate, you can speed this process by clicking 'Report this comment' (or, if that doesn't work for you, email webadmin@nature.com). For more controversial topics, we reserve the right to moderate before comments are published.
Test